Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
|Articles|February 20, 2013
Highlights from iPharma 2013: Tweet Roundup
Author(s)Clark Herman
CBI’s 12th Annual Digital Innovation Forum, better known as iPharma, covered a broad range of topics from maintaining salient SEO strategy to effectively managing digital project pipelines across different departments.
Advertisement
CBI’s 12th Annual Digital Innovation Forum, better known as iPharma, covered a broad range of topics from maintaining salient SEO strategy to effectively managing digital project pipelines across different departments. Watch the video below for some of the conversation around the presentations, or to read a more in-depth account, click
Advertisement
Related to this article
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
A conversation with Geoffrey T. Sanzenbacher, a research fellow at the Center for Retirement Research.
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
Advertisement
Advertisement
Trending on PharmExec
1
Bausch + Lomb Appoints Thomas Appio as Interim CEO
2
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
3
The Manufacturing Issues That Continue to Contribute to Drug Shortages
4
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
5